Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
GLPGF - GALAPAGOS NV
Market Cap 2.85B P/E - EPS this Y - Ern Qtrly Grth 76.10%
Income 31.5M Forward P/E - EPS next Y - 50D Avg Chg 4.00%
Sales 261.4M PEG - EPS past 5Y - 200D Avg Chg 5.00%
Dividend N/A Price/Book 1.08 EPS next 5Y - 52W High Chg -22.00%
Recommedations - Quick Ratio 9.68 Shares Outstanding 65.90M 52W Low Chg 22.00%
Insider Own 25.36% ROA -1.76% Shares Float 44.54M Beta 0.09
Inst Own 22.97% ROE 1.15% Shares Shorted/Prior -/- Price 41.75
Gross Margin -13.57% Profit Margin 108.11% Avg. Volume 83 Target Price -
Oper. Margin -49.03% Earnings Date Oct 30 Volume 150 Change 0.00%
Healthcare | Biotechnology | Belgium
About GALAPAGOS NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

GALAPAGOS NV News
11/05/24 Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
11/02/24 Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023)
11/01/24 Galapagos NV (GLPG) Q3 2024 Earnings Call Highlights: Strong Cash Position and R&D Progress ...
10/30/24 Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
10/07/24 Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
09/30/24 Galapagos receives transparency notification from EcoR1 Capital
09/03/24 Galapagos receives transparency notification from FMR LLC
09/01/24 Even after rising 13% this past week, Galapagos (AMS:GLPG) shareholders are still down 82% over the past five years
08/28/24 Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
06:43 AM Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
12:00 AM Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
08/12/24 ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload
08/01/24 Galapagos reports half-year 2024 financial results and provides second quarter business update
08/01/24 BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology
06/14/24 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
06/13/24 Retail investors are Galapagos NV's (AMS:GLPG) biggest owners and were hit after market cap dropped €74m
05/30/24 Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
05/30/24 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
05/16/24 Galapagos creates new subscription right plans
05/15/24 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.